Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desvenlafaxine for menopausal vasomotor symptoms
NCT00256685Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in vasomotor symptoms comparing Desvenlafaxine Succinate with Placebo (2 arms). Primary endpoints: Reduction in average daily number of moderate & severe hot flushes at 12 weeks and Reduction in average daily severity score at 12 weeks. Started Sep 2004; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT00256685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00256685.